Findings

What do systematic reviews say?

10 questions · 12 findings · 2 reviews · Developmental, Psychosocial and Learning Problems

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 16.7%GRADE not reported 0 · 0%Very low 2 · 16.7%Low 5 · 41.7%Moderate 3 · 25%High 0 · 0%

RISPERIDONE vs placebo

Aggression · Disruptive behaviours in children and youths

2 findings from 1 review

Atypical antipsychotics for disruptive behaviour disorders in children and youths 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 238 participants
Low
Atypical antipsychotics for disruptive behaviour disorders in children and youths 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 190 participants
Moderate

RISPERIDONE vs placebo

Conduct · Disruptive behaviours in children and youths

1 finding from 1 review

Atypical antipsychotics for disruptive behaviour disorders in children and youths 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 225 participants
Moderate

RISPERIDONE vs placebo

Weight gain · Disruptive behaviours in children and youths

2 findings from 1 review

Atypical antipsychotics for disruptive behaviour disorders in children and youths 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 138 participants
Moderate
Atypical antipsychotics for disruptive behaviour disorders in children and youths 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 305 participants
Low

Galantamine plus risperidone vs placebo plus risperidone

Overall autism features Not assessed · children and adolescents with a diagnosis of autism

The review found no eligible studies for this question.

1 finding from 1 review

Acetylcholinesterase inhibitors for autistic spectrum disorders 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Galantamine plus risperidone vs placebo plus risperidone

Social communication (Lethargy/Social withdrawal subscale of the ABC‐C; 0 to 64; lower = better) · children and adolescents with a diagnosis of autism

1 finding from 1 review

Acetylcholinesterase inhibitors for autistic spectrum disorders 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Very low

Galantamine plus risperidone vs placebo plus risperidone

Stereotypical behaviours · children and adolescents with a diagnosis of autism

1 finding from 1 review

Acetylcholinesterase inhibitors for autistic spectrum disorders 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Very low

Galantamine plus risperidone vs placebo plus risperidone

Side effects or other adverse events · children and adolescents with a diagnosis of autism

Galantamine plus risperidone may leads to higher adverse events (Side Effects Checklist) compared with placebo plus risperidone (low certainty).

1 finding from 1 review

Acetylcholinesterase inhibitors for autistic spectrum disorders 2023 · Cochrane Headline outcomes only
OR 5.57 [1.42, 21.86]
1 study · 40 participants
Low

Galantamine plus risperidone vs placebo plus risperidone

Irritability · children and adolescents with a diagnosis of autism

1 finding from 1 review

Acetylcholinesterase inhibitors for autistic spectrum disorders 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Low

Galantamine plus risperidone vs placebo plus risperidone

Hyperactivity · children and adolescents with a diagnosis of autism

1 finding from 1 review

Acetylcholinesterase inhibitors for autistic spectrum disorders 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Low

Galantamine plus risperidone vs placebo plus risperidone

General health and function Not assessed · children and adolescents with a diagnosis of autism

The review found no eligible studies for this question.

1 finding from 1 review

Acetylcholinesterase inhibitors for autistic spectrum disorders 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found